PIN78 Cost Utility of Infant Vaccination Against Respiratory Syncytial Virus Infection in the Netherlands  by Meijboom, M. et al.
versus DRV/r. CONCLUSIONS: The value of initiation with ATV/r in terms of dura-
ble viral suppression and favourable side-effect profile was most prominent in
Spain. In general, starting with ATV/r is suggested to be a cost-effective treatment
strategy for HIV-1 treatment-naïve patients in most of the country-specific com-
parisons made.
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OBJECTIVES: Streptococcus pneumoniae is a leading cause of life-threatening pneu-
mococcal diseases (PDs). In Germany, PPV23 has been recommended in the elderly
(aged 60 and over) since 1998. In 2006, the pneumococcal conjugate vaccine (PCV)
was introduced in children. The US experience showed that PCV vaccination of
children led, ten years after its introduction, to a decrease in IPD incidence caused
by the PCV serotypes not only in vaccinated children but also in unvaccinated
adults. This study aimed to re-assess the good cost-effectiveness profile of PPV23
vs. no vaccination (NoVac) in the elderly in Germany, accounting for epidemiolog-
ical changes in adults due to PCV vaccination of children.METHODS:A population-
based Markov model was developed, consisting of five health states: no PD, IPD
(invasive PD), NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis
sequelae (PMS) and death. A cohort of individuals was followed until death assum-
ing vaccination or no vaccination. IPD and NBPP incidence were retrieved from
German sources, while the changes in IPD incidence were estimated based on US
data. IPD and NBPP case-fatality rates, probability of developing PMS, vaccine ef-
fectiveness, vaccine waning function and utilities were retrieved from the pub-
lished literature. A discount rate of 3% was applied to costs and effects. RESULTS:
PPV23 was associated with a discounted increment of 1,587 QALYs. From the third
party payer’s (TPP) perspective, incremental costs were estimated at €28 million
and the ICER was €17,700/QALY gained. From the societal perspective, PPV23 was
associated with an increment of €14 million, and the ICER was €8579/QALY gained.
Results were sensitive to vaccine effectiveness and epidemiological trends
assumptions. CONCLUSIONS: The model suggests that vaccinating the elderly
with PPV23 is cost-effective in Germany. As PPV23 covers 80%-90% of all serotypes
causing IPD, it is still cost-effective despite the reduction in IPD incidence in adults
due to PCV vaccination of children.
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Vaccination of elderly (65 and older) population against Streptococcus pneumonia
is recommended in Poland but not publicly funded. Therefore coverage rates for
pneumococcal vaccine have remained very low (less than 1%) meaning that no
benefit of the vaccine has been felt in Poland and individuals remain largely
unprotected. OBJECTIVES: An analysis was designed to analyse the cost-effective-
ness of implementing a public vaccination programme in the elderly considering a
50% reimbursement of a 23-valent polysaccharide vaccine (PPV23) by the public
health care payer: Narodowy Fundusz Zdrowia (NFZ). METHODS: To do so, a semi-
dynamic Markov model with a 1-year cycle length was developed, allowing up to 10
cohorts to enter the model over the lifetime horizon. The model was populated
with demographic, epidemiological and cost data from Polish sources or when
unavailable, from international literature. The analysis included routine vaccina-
tion of all elderly or high-risk (HR) elderly versus no vaccination. Deterministic and
probabilistic sensitivity analyses (DSA and PSA, respectively) were conducted to
assess the robustness of the cost-effectiveness results. RESULTS: The vaccination
program targeting all elderly in Poland would avoid 8935 pneumococcal infections,
2542 hospitalisations, 671 deaths; for HR elderly the program would avoid 5886
infections, 1673 hospitalisations and 441 deaths. The incremental cost per QALY
gained for vaccination in all elderly was PLN 3382 and was PLN 2148 for HR elderly.
Ratios were even lower when actual in and outpatients’ costs instead of reim-
bursed costs were considered. Finally, ratios estimated in the base case and the
sensitivity analyses, were well below the gross domestic product (GDP) per capita
(i.e. PLN 37,055). CONCLUSIONS: This analysis suggests that vaccinating all elderly
regardless of risk status with a 23-valent pneumococcal vaccine is highly cost-
effective and supports the continued recommendation of pneumococcal vaccines,
as well as their public funding in Poland.
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OBJECTIVES: According to World Health Organization, pneumococcal related dis-
eases is a major public health concern in the world, especially for those under 2
years of age and older adults. The objective of this analysis is to evaluate the cost
effectiveness of vaccinating the Brazilian population 65 years of age and older with
the 13-valent pneumococcal conjugate vaccine (PCV 13) in comparison to the 23-
valent pneumococcal polysaccharide vaccine (PPV 23), each as a single dose, from
the public payer perspective. METHODS: In order to estimate the costs and the
impact of the pneumococcal disease over a 35-year time horizon period, including
invasive pneumococcal disease, hospitalized pneumonia and non complicated
pneumonia, a patient level microsimulation model simulating vaccination and
outcomes of one cohort of 12,653,613 individuals over 65 years of age was adapted
to the Brazilian public health care system. The probabilities and direct medical
costs were extracted from literature review and DATASUS for January 2011, with
costs presented in US$ 2010. The effectiveness measures were expressed as cases
of pneumococcal diseases avoided, overall deaths avoided, and life years (LYs)
saved. Probabilistic sensitivity analyses were conducted considering key variables.
A discount rate of 5% was applied. RESULTS: Vaccinating with PCV13 prevents 349
additional cases of acute meningitis, 1,589 cases of invasive pneumococcal disease,
100,158 hospitalized pneumonia, 12,954 non complicated pneumonia and 30,904
deaths, saving 139,189,74 LYs compared to PPV23 over 35 years. The total costs
including vaccination costs and medical costs resulted in US$135,625,000 less for
PCV13 compared to PCV23 (US$5,875,625,000 vs. US$5,740,000,000). The model
showed robustness through sensitivity analyses.CONCLUSIONS:The analysis sug-
gests that vaccinating adults with PCV13 in Brazil is cost-saving compared to
PPV23. The results in economic and disease burden are substantial and they sup-
port the decision making in favor of PCV13 for its high impact in public health.
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OBJECTIVES: Systemic Candida infections (SCI) occur predominantly in intensive
care unit (ICU) patients and are a common cause of morbidity and mortality. The
increasing prevalence of SCI caused by Candida non-albicans species and higher
resistance to fluconazole and azoles in general have prompted changes in the
management of SCI. Current guidelines tend to favour treatment initiation with a
broad spectrum antifungal such as an echinocandin with subsequent switch to
fluconazole if isolates are sensitive (de-escalation) over the traditional first-line
treatment with fluconazole (escalation). Cost-effectiveness of de-escalation strat-
egy versus escalation in patients with SCI was evaluated from the UK NHS
perspective. METHODS: Cost-effectiveness was estimated using decision analysis
based on clinical and microbiological data from pertinent studies. The model ho-
rizon was 42 days, and was extrapolated to cover a life time horizon. RESULTS: In
patients with fluconazole-resistant isolates, de-escalation avoids 30% more deaths
and successfully treats 23% more patients than escalation, with cost savings of
£1621 per treated patient. In the overall population with SCI, initial treatment with
micafungin results in 1.2% fewer deaths at a marginal cost of £740 per patient alive.
Over a lifetime horizon, the incremental cost effectiveness of de-escalation com-
pared with escalation is £15,522 per life-year and £25,673 per QALY. Univariate
analyses indicate that the incremental costs per QALY of de-escalation are highly
sensitive to the fluconazole-susceptibility profile, late mortality in fluconazole-
resistant infections, fluconazole clinical success rate, excess hospitalization, life
expectancy, underlying diseases and follow-up costs. CONCLUSIONS: The de-es-
calation strategy is associated with better clinical outcomes and improved survival,
particularly among patients with fluconazole-resistant Candida strains. De-esca-
lation from initial treatment with micafungin is a cost effective alternative to tra-
ditional escalation approach from a UK NHS perspective with a differential cost per
QALY below the recognised willingness to pay threshold of £30,000.
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OBJECTIVES: Respiratory syncytial virus (RSV) infection is one of the major causes
of respiratory symptoms in infants in many countries, infecting virtually every
child by the age of two. Currently, several Phase 1 trials with RSV vaccines in
infants are running or have been completed. Although no efficacy estimates are yet
available, cost-effectiveness estimates might be informative enabling preliminary
positioning. METHODS: A decision analysis model was developed following a
Dutch birth cohort for 12 months. Vaccination strategies that were reviewed in-
cluded vaccination at specific ages, different dosing schemes and seasonal versus
year round vaccination. The impact of the assumptions was explored in sensitivity
analyses. Outcome measures included number of GP visits, hospitalizations and
deaths, costs, quality-adjusted life years and ICERs. RESULTS: Without vaccina-
tion, an annual number of 28,738 of RSV-related GP visits, 1,623 hospitalizations,
and 4.5 deaths are estimated in the 0-1 year olds. The total cost to society in the
non-vaccination scenario was €7.7 million and the annual disease burden was
estimated at 597 QALYs. In case all infants would be offered a 3-dose RSV vaccina-
tion scheme at 0/1/3 months of age, the total annual net costs were estimated to
increase to €21.2 million but a significant number of hospitalizations and deaths
could be averted, 544 and 1.5 respectively. The ICER was estimated € 34,142 (95%CI:
€ 21,652 - € 87,766) per QALY. A reduced dose schedule, seasonal vaccination, out-of
pocket payments all resulted in a more favorable ICERs while lowering the ex-
pected vaccine efficacy or delaying the time of vaccination in less favorable ICERs.
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CONCLUSIONS: Recent updates on burden of disease estimates were used and
utilities included but due to the absence of trial data still a number of assumptions
were used. The outcomes of this modeling exercise show that a vaccine against
RSV might be cost-effective, but trial data are warranted.
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OBJECTIVES:To compare cost-effectiveness of tenofovir and other AN in treatment
of adults with CHB in Poland. METHODS: Analysis was performed from the public
payer perspective. A lifetime Marcov model (3-month cycle) was developed defin-
ing heath states based on HBV_DNA level. Following events were included: com-
plications (liver cirrhosis, hepatocellular carcinoma), drug resistance and relapse
after remission. Analysis was performed in total population (regardless of the
HBeAg status) and in subpopulation of HBeAg() patients. Analysis for HBeAg(-)
patients was impossible to conduct due to lack of effectiveness data. Effectiveness
parameters were based on MTC conducted in systematic review of randomized
clinical trials. In the analysis following costs were included: antiviral drugs, mon-
itoring, hospitalization and CHB complications treatment. The reliability of the
estimates was examined by sensitivity analyses of model parameters. RESULTS: In
total population the estimated lifetime QALY per patient were: 12.33 for tenofovir,
11.32 for entecavir and 11.64 for adefovir. The estimated differences in QALYs
between tenofovir and comparators were: 1.00 in comparison to entecavir and 0.69
in comparison to adefovir. The differences were not statistically significant. Aver-
age lifetime costs per patient were: 223,519 PLN for tenofovir, 358,565 PLN for en-
tecavir and 349,535 PLN for adefovir. The resulting difference in costs between
tenofovir and comparators were: -135,045 PLN in comparison to entecavir and
-126,016 PLN in comparison to adefovir. The results for HBeAg() subpopulation
were close to results for total population. CONCLUSIONS: Both in total population,
as well as in HBeAg() subpopulation, tenofovir dominates adefovir and entecavir,
which means that it allows for greater health effects (QALY, LYG) with lower costs
of treatment. Results of probabilistic sensitivity analysis indicates that tenofovir
therapy is cost-effective (for the assumed threshold of three GDP: 102,045 PLN) with
a probability of ca 82% when compared with adefovir and ca 86% in comparison to
entecavir.
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OBJECTIVES: In 2011, intranasal administrated live-attenuated influenza vaccine
(LAIV) for prophylaxis of seasonal influenza was approved in the EU for children
aged 2-17 years. Our objective was to estimate the potential epidemiological impact
and cost-effectiveness of the current policy to vaccinate people over 60 years and
people with underlying chronic conditions with trivalent inactivated vaccine (TIV)
compared to the addition of routine childhood vaccination with LAIV in Germany.
METHODS: A compartmental susceptible-exposed-infectious-recovered-suscepti-
ble (SEIRS) model populated with German specific data was developed to explore
the impact of vaccination on the transmission dynamics of seasonal influenza. In
addition, a decision tree was constructed to incorporate several consequences of
influenza infections and to compare costs and outcomes of different vaccination
strategies in the German health care setting. The time horizon was set to ten years
after the introduction of LAIV, assuming childhood vaccination coverage of 70%.
Input data were based on published literature or were derived by expert consulting
using the Delphi technique. RESULTS: Under base-case assumptions, annual rou-
tine vaccination of children would prevent 8.8 million influenza illnesses, resulting
in a reduction of 273,124 cases of acute otitis media and 68,102 cases of community-
acquired pneumonia over ten years if left undiscounted. The discounted incremen-
tal cost-effectiveness ratio was €9601 per QALY gained from a third-party payer
perspective, when compared to the current strategy of vaccinating only risk groups
with TIV. Inclusion of patient co-payments and indirect costs resulted in a dis-
counted 10-year cost-saving to society of €1.16 billion. CONCLUSIONS: Compared
with the current vaccination policy, introducing childhood and adolescent vacci-
nation with LAIV can substantially increase benefits and reduce overall costs when
adopting a societal perspective. Using the commonly cited threshold of €50,000 per
QALY gained, routine vaccination of children with LAIV can be considered cost-
effective from a third-party payer perspective.
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OBJECTIVES: This study aims to evaluate the cost-effectiveness of peg-interferon
alpha-2a plus ribavirin compared with conventional interferon alpha-2a plus riba-
virin for the treatment of chronic hepatitis C (CHC) in China. METHODS: A Markov
health-state model was designed to estimate the direct medical costs and out-
comes (life year gained and quality adjusted life year, QALY) of treating CHC. The
model consists of 7 health states: cured (sustained virological response), CHC, com-
pensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver
transplant, and death. Based on literature research, a two-round expert panel sur-
vey was conducted among experienced clinicians nationally in China to identify
medical cost and clinical efficacy data. The evaluation was conducted from a per-
spective of China’s health insurance system to compare combination therapy sce-
narios of peg-interferon alfa-2a (40KD) plus ribavirin with conventional interferon
alfa-2a plus ribavirin. The evolution of a cohort of CHC patients was simulated
along 40 years with yearly cycles. A discounting rate at 3% was used to discount
utilities and medical costs happened at different years. A univariate sensitivity
analysis was performed to understand the key drivers and general sensitivity of the
model. RESULTS: The model showed that peg-interferon alpha-2a scenario could
prolong 2.25 (30.02 years vs. 27.77 years) total life years compared with conven-
tional interferon alpha-2a scenario. The discounted QALYs generated by peg-inter-
feron were 2.19 longer than that of conventional interferon (18.58 QALYs vs. 16.39
QALYs). The discounted mean total cost per patient treated with peg-interferon
alpha-2a scenario was 114,751 CNY (US$17,930), and 130,047 CNY (US$20,320) for
patient treated with conventional interferon. CONCLUSIONS: The results of the
model suggest that peg-interferon alfa-2a treatment is dominant in both health
outcomes and long-term treatment costs compared with conventional interferon
alpha-2a for the treatment of CHC, which means peg-interferon alfa-2a treatment
can generate cost savings for the China’s health insurance system.
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OBJECTIVES: Atazanavir/r (ATV/r) and darunavir/r (DRV/r) are commonly used to
suppress HIV in Germany. Compared to lopinavir/r, both have demonstrated sim-
ilar relative efficacy in randomized clinical trials (RCT) in previously untreated
patients; whereas annual drug acquisition costs are 250 euro more for DRV/r. How-
ever, the objective was to estimate how these would translate into costs and ef-
fects, after 5 and 25 years. METHODS: The cost-effectiveness was forecasted using
a microsimulation-model (monthly cycles) for previously untreated HIV-patients
Response to medication was modeled as a reduction in HIV-RNA viral-load. In
accordance with literature, increase in CD4 could persist up to 5 years while
having a response; whereas no response resulted in the opposite. The occurrences
of AIDS defining events and non-AIDS defining malignancies were linked to the
current CD4 and independent of therapy. Adverse events (AE) on the other hand
were treatment-specific and the following were considered: 1) diarrhea; 2) dizzi-
ness; 3) jaundice; 4) nausea; and 5) rash. Toxicities associated with the long-term
use of agents considered in the model included: 1) cardiovascular events; 2) renal
insufficiency; and 3) hepatic failure. Drug efficacy and AE incidences were based on
published RCTs - compared via an indirect comparison - whereas, other data was
based on published literature. RESULTS: After 5 years, initiation with ATV/r use
was found to be associated with a lower total cost compared to DRV/r. In the
long-term (i.e. 25 year time horizon) the use of ATV/r was found to be associated
with an increase in survival of 16.0 (discounted) years; 0.31 life years and 0.55
QALYs compared to DRV/r. This resulted in an ICUR of € 11,241 per QALY gained.
Results were most sensitive to changes in virological parameters, market shares for
future lines and cost per CD4-level. CONCLUSIONS: The model forecasts ATV/r to
be cost-effective compared to DRV/r in Germany.
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OBJECTIVES: To assess cost-effectiveness of CMV disease prophylaxis prolonga-
tion in kidney transplant recipients from 110 to 200 days from Polish public payer’s
perspective. METHODS: Clinical efficacy and safety of prolonged to 200 days pro-
phylaxis of CMV disease in kidney transplant recipients (D/R-) was assessed in
systematic review. Following measurable differential direct medical costs were
estimated and included: costs of drugs and diagnostic, hospital/ambulatory proce-
dures, adverse events treatment, acute rejection, CMV disease treatment, oppor-
tunistic infections treatment, hemodialysis and subsequent kidney transplanta-
tion. Cost data were gathered in 4 medical centers. Markov model was used to
calculate costs and efficacy in 23.5 years time horizon - the maximum expected
survival of kidney transplant recipient. Costs and clinical effects were discounted
(5% for costs and effects, 0% for costs and effects, 5% for costs and 0% for effects).
Probabilistic, one-way, multiway sensitivity analyses were conducted. RESULTS:
The prolongation to 200 days of CMV disease prophylaxis in kidney transplant
recipients is lined to reduction in frequency of CMV infections, acute transplant
rejections, loss of graft functions and need of subsequent kidney transplantation.
In the 23.5 years gain of 0.3846 life years and 0.3178 quality adjusted life years can
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